1. Home
  2. ANTX vs BNR Comparison

ANTX vs BNR Comparison

Compare ANTX & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AN2 Therapeutics Inc.

ANTX

AN2 Therapeutics Inc.

HOLD

Current Price

$1.19

Market Cap

30.1M

Sector

Health Care

ML Signal

HOLD

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$16.35

Market Cap

233.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANTX
BNR
Founded
2017
2014
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.1M
233.7M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
ANTX
BNR
Price
$1.19
$16.35
Analyst Decision
Buy
Analyst Count
1
0
Target Price
$2.00
N/A
AVG Volume (30 Days)
54.8K
68.6K
Earning Date
11-12-2025
11-20-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$75,749,382.00
Revenue This Year
N/A
$136.32
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
5.56
52 Week Low
$1.01
$2.18
52 Week High
$1.55
$23.59

Technical Indicators

Market Signals
Indicator
ANTX
BNR
Relative Strength Index (RSI) 61.12 49.77
Support Level $1.12 $15.64
Resistance Level $1.21 $18.42
Average True Range (ATR) 0.07 2.44
MACD 0.02 -0.61
Stochastic Oscillator 86.36 20.46

Price Performance

Historical Comparison
ANTX
BNR

About ANTX AN2 Therapeutics Inc.

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

Share on Social Networks: